Maternal hemodynamics in screen-positive and screen-negative women of the ASPRE trial.


Journal

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
ISSN: 1469-0705
Titre abrégé: Ultrasound Obstet Gynecol
Pays: England
ID NLM: 9108340

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 13 06 2018
revised: 11 09 2018
accepted: 13 09 2018
pubmed: 25 9 2018
medline: 28 1 2020
entrez: 25 9 2018
Statut: ppublish

Résumé

To compare maternal hemodynamics and perinatal outcome, in pregnancies that do not develop pre-eclampsia (PE) or deliver a small-for-gestational-age (SGA) neonate, between those identified at 11-13 weeks' gestation as being screen positive or negative for preterm PE, by a combination of maternal factors, mean arterial pressure, uterine artery pulsatility index, serum placental growth factor and pregnancy associated plasma protein-A. This was a prospective longitudinal cohort study of maternal cardiovascular function, assessed using a bioreactance method, in women undergoing first-trimester screening for PE. Maternal hemodynamics and perinatal outcome were compared between screen-positive and screen-negative women who did not have a medical comorbidity, did not develop PE or pregnancy-induced hypertension and delivered at term a live neonate with birth weight between the 5 The screen-negative group (n = 926) had normal cardiac function changes across gestation, whereas the screen-positive group (n = 170) demonstrated static or reduced cardiac output and stroke volume and higher mean arterial pressure and peripheral vascular resistance with advancing gestation. In the screen-positive group, compared with screen-negative women, birth-weight Z-score was shifted toward lower values, with prevalence of delivery of a neonate below the 35 Women who were screen positive for impaired placentation, even though they did not develop PE or deliver a SGA neonate, had pathological cardiac adaptation in pregnancy and increased risk of adverse perinatal outcome. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

Identifiants

pubmed: 30246326
doi: 10.1002/uog.20125
doi:

Substances chimiques

PGF protein, human 0
Placenta Growth Factor 144589-93-5
Pregnancy-Associated Plasma Protein-A EC 3.4.24.-

Types de publication

Clinical Trial Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

51-57

Subventions

Organisme : Fetal Medicine Foundation
ID : 1037116

Informations de copyright

Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

Auteurs

H Z Ling (HZ)

Fetal Medicine Research Institute, King's College London, London, UK.

G P Guy (GP)

Fetal Medicine Research Institute, King's College London, London, UK.

A Bisquera (A)

School of Population Health & Environmental Sciences, King's College London, London, UK.
NIHR Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK.

L C Poon (LC)

Fetal Medicine Research Institute, King's College London, London, UK.
Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong, China.

K H Nicolaides (KH)

Fetal Medicine Research Institute, King's College London, London, UK.

N A Kametas (NA)

Fetal Medicine Research Institute, King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH